Last reviewed · How we verify

Etoposide, Thioguanine, Cyclophosphamide, Busulfan, Melphalan

Dutch Childhood Oncology Group · Phase 3 active Small molecule

Etoposide, Thioguanine, Cyclophosphamide, Busulfan, Melphalan is a Multi-agent chemotherapy regimen; alkylating agents, antimetabolite, topoisomerase II inhibitor Small molecule drug developed by Dutch Childhood Oncology Group. It is currently in Phase 3 development for Conditioning regimen for hematopoietic stem cell transplantation in pediatric acute leukemia, Pediatric hematologic malignancies requiring myeloablative therapy.

This is a multi-drug chemotherapy regimen that kills cancer cells through multiple mechanisms including DNA alkylation, purine antagonism, and topoisomerase II inhibition.

This is a multi-drug chemotherapy regimen that kills cancer cells through multiple mechanisms including DNA alkylation, purine antagonism, and topoisomerase II inhibition. Used for Conditioning regimen for hematopoietic stem cell transplantation in pediatric acute leukemia, Pediatric hematologic malignancies requiring myeloablative therapy.

At a glance

Generic nameEtoposide, Thioguanine, Cyclophosphamide, Busulfan, Melphalan
SponsorDutch Childhood Oncology Group
Drug classMulti-agent chemotherapy regimen; alkylating agents, antimetabolite, topoisomerase II inhibitor
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 3

Mechanism of action

The combination includes cyclophosphamide and busulfan (alkylating agents that cross-link DNA), melphalan (nitrogen mustard alkylating agent), thioguanine (purine analog that inhibits nucleotide synthesis), and etoposide (topoisomerase II inhibitor that prevents DNA repair). Together, these agents work synergistically to damage cancer cell DNA and prevent replication, commonly used as a myeloablative conditioning regimen prior to hematopoietic stem cell transplantation.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Etoposide, Thioguanine, Cyclophosphamide, Busulfan, Melphalan

What is Etoposide, Thioguanine, Cyclophosphamide, Busulfan, Melphalan?

Etoposide, Thioguanine, Cyclophosphamide, Busulfan, Melphalan is a Multi-agent chemotherapy regimen; alkylating agents, antimetabolite, topoisomerase II inhibitor drug developed by Dutch Childhood Oncology Group, indicated for Conditioning regimen for hematopoietic stem cell transplantation in pediatric acute leukemia, Pediatric hematologic malignancies requiring myeloablative therapy.

How does Etoposide, Thioguanine, Cyclophosphamide, Busulfan, Melphalan work?

This is a multi-drug chemotherapy regimen that kills cancer cells through multiple mechanisms including DNA alkylation, purine antagonism, and topoisomerase II inhibition.

What is Etoposide, Thioguanine, Cyclophosphamide, Busulfan, Melphalan used for?

Etoposide, Thioguanine, Cyclophosphamide, Busulfan, Melphalan is indicated for Conditioning regimen for hematopoietic stem cell transplantation in pediatric acute leukemia, Pediatric hematologic malignancies requiring myeloablative therapy.

Who makes Etoposide, Thioguanine, Cyclophosphamide, Busulfan, Melphalan?

Etoposide, Thioguanine, Cyclophosphamide, Busulfan, Melphalan is developed by Dutch Childhood Oncology Group (see full Dutch Childhood Oncology Group pipeline at /company/dutch-childhood-oncology-group).

What drug class is Etoposide, Thioguanine, Cyclophosphamide, Busulfan, Melphalan in?

Etoposide, Thioguanine, Cyclophosphamide, Busulfan, Melphalan belongs to the Multi-agent chemotherapy regimen; alkylating agents, antimetabolite, topoisomerase II inhibitor class. See all Multi-agent chemotherapy regimen; alkylating agents, antimetabolite, topoisomerase II inhibitor drugs at /class/multi-agent-chemotherapy-regimen-alkylating-agents-antimetabolite-topoisomerase-ii-inhibitor.

What development phase is Etoposide, Thioguanine, Cyclophosphamide, Busulfan, Melphalan in?

Etoposide, Thioguanine, Cyclophosphamide, Busulfan, Melphalan is in Phase 3.

What are the side effects of Etoposide, Thioguanine, Cyclophosphamide, Busulfan, Melphalan?

Common side effects of Etoposide, Thioguanine, Cyclophosphamide, Busulfan, Melphalan include Myelosuppression/neutropenia, Mucositis, Nausea and vomiting, Hepatotoxicity, Secondary malignancy, Infertility.

Related